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Whilst recent large-scale studies have provided much evidence on the natural history and ther-
apeutic response in patients with chronic obstructive pulmonary disease (COPD), relatively
little is known about the effect in younger patients.
We report a pre-specified post-hoc analysis of 356 patients with COPD  50 years old from
the four year randomised, double blind placebo controlled Understanding Potential Long Term
Impact on Function with Tiotropium (UPLIFT) trial. Inclusion criteria included a post-broncho-
dilator forced expiratory volume in 1 s (FEV1) of 70%, FEV1/FVC < 0.70, age 40 years, and
smoking history of 10 pack years.
Younger patients had a mean FEV1 of 1.24 L (39% predicted) and an impaired health-related
quality of life (St. George’s Respiratory Questionnaire (SGRQ)) compared to the entire UPLIFT
population. There were 40.2% women and 51.1% current smokers in the younger age group.
Tiotropium was associated with a sustained improvement in spirometry and SGRQ. Mean
decline in post-bronchodilator FEV1 was 58 ml/year (placebo) vs. 38 ml/year (tiotropium)
(p Z 0.01). Corresponding values for pre-bronchodilator FEV1 were 41 ml/year (placebo)
compared with 34 ml/year (tiotropium) (pZ 0.34). The hazard ratio (95%CI) for an exacerba-
tion in the younger age group was 0.87(0.68, 1.13)). The rate of exacerbations was reduced by
tiotropium (rate ratio (95%CI) Z 0.73(0.56, 0.95)).82 622308/624067; fax: þ44 1482 624068.
c.uk (A.H. Morice).
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1660 A.H. Morice et al.Tiotropium resulted in sustained bronchodilation, improved quality of life, and a decreased
exacerbation rate in younger patients. Tiotropium also resulted in a significant reduction in the
decline in post-bronchodilator FEV1, suggesting possible disease modification by tiotropium in
younger patients with COPD.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a progres-
sive debilitating disease which usually presents in later life
with exertional dyspnoea. Partially reversible airflow
obstruction as a consequence of long term tobacco smoking
is the defining feature of the condition and the prevalence
increases with increasing pack years.1 A subgroup of
smokers appears particularly vulnerable to the effects of
tobacco smoke and develops COPD in their early years.2
However, little is known of the natural history or response
to therapy in these younger individuals.
There have been substantial improvements in the
therapy of COPD with the introduction of long-acting beta
agonists,3 long-acting anticholinergic drugs,4 and inhaled
steroid/long acting beta agonist combination products.5,6
These agents have been demonstrated to improve
a variety of physiologic and symptom parameters associ-
ated with the disease. Lung function, exercise duration and
health-related quality of life are enhanced and exacerba-
tion frequency decreased. Additionally, two recent large-
scale studies have demonstrated a reduction of mortality
approaching or above statistical and clinical significance.7,8
What has been harder to demonstrate is a significant effect
on the progressive decline in lung function seen in COPD.
Until recently the only intervention to demonstrate an
impact on the rate of decline of lung function was smoking
cessation.9 Publications based on the UPLIFT10 and
TORCH7 studies have indicated the potential for pharma-
cotherapy to slow the decline in lung function in COPD. The
demonstration of such potential disease modification with
pharmacotherapy has important implications in the future
management of the condition with respect to the utility of
screening and early intervention.
Here we present a subgroup analysis of a pre-specified
cohort of young patients from the UPLIFT trial who were
50 years of age on entry into the study. The objective of
this analysis was to assess the 4-year progression of COPD
and the effect of tiotropium in a subgroup of patients
between the ages of 40 and 50 years who participated in
the UPLIFT trial.Methods
Study design
The study design andmain results from theUPLIFTstudy have
been reported elsewhere.11 Briefly, UPLIFT was a rando-
mised, double blind, parallel-group trial of once daily tio-
tropium in patients with spirometrically proven COPD older
than or equal to 40 years of age. The post-bronchodilator
FEV1was required to be 70%or less of the predicted value andto be 70% or less than the FVC. A smoking history of greater
than 10 pack years and a physician diagnosis of COPD were
required for entry. The study was undertaken in 487 centres
in 37 countries. The study was approved by the local ethical
review boards of the participating centres and registered
(ClinicalTrials.gov:NCT00144339). Of note, in addition to the
study medication, all patients could receive all prescribed
respiratory medications, other than inhaled anticholiner-
gics, throughout the trial.
The two treatment arms were tiotropium (18 mcg once
daily) or matched placebo delivered via the HandiHaler
inhalation device (Boehringer Ingelheim, Ingelheim,
Germany). At the end of the four year study period (approxi-
mately day 1440) all patients were asked to stop the trial
medication and were prescribed ipratropium two actuations
(40 mcg) four times daily and asked to return for a further
assessment 30 days later (approximately day 1470).
Following randomisation patients were seen at onemonth
and three months with follow-up at three monthly intervals
thereafter for four years. Spirometry (ATS criteria) was
performed in accordance with strict quality control stan-
dards to obtain FEV1, FVCand slowvital capacity (SVC). Every
six months patients were asked to withhold their respiratory
medication on the day of testing and pre-bronchodilator
spirometry was performed. Study drug was then adminis-
tered and patients given 80mcg ipratropium followed 60min
later by 400mcg salbutamol. Thirtyminutes after salbutamol
post-bronchodilator spirometry was performed. The yearly
rates of decline in pre- and post-bronchodilator FEV1 from
day 30 until the completion of double blinded treatment
were the co-primary endpoints. Secondary endpoints were
three monthly lung functions, health-related quality of life
as measured by the St. George’s Respiratory Questionnaire
(SGRQ), exacerbations and exacerbations requiring hospital
admission, and mortality from all causes. Mortality data was
analyzed during the period from the first treatment day up
until 30 days following the last dose of studymedication (‘on-
treatment’), during the planned four years (1440 days) of
study treatment and during the protocol defined period plus
a 30 day washout period (1470 days). The latter two analyses
included the vital status information of prematurely dis-
continued patients.
Statistical analysis
The co-primary endpoints and secondary endpoints of FVC,
SVC and total score of SGRQ were analysed using random
effects models. The decline of pulmonary function over
time was analysed with random coefficient regression in
which the pulmonary function value changed linearly after
30 days for each patient. The intercepts and slopes were
random and the treatment effects were fixed. The mean
effects at particular visits were estimated using repeated
COPD in young patients 1661measures analysis of covariance models, which did not
require imputation of missing values. Time to first exacer-
bation and exacerbation-related hospitalisation was
compared using Cox regression. The number of exacerba-
tions and those leading to hospitalisation were estimated
using Poisson regression, with adjustment for over disper-
sion and treatment exposure. None of the analyses have
been adjusted for multiple comparisons.Results
Patient characteristics
Of the 5993 patients randomised in UPLIFT, 356 were aged
50 years or younger. The flow of patients into the study is
described in the CONSORT diagram (Fig. 1). The baseline
characteristics of these younger patients and those aged
over 50 years of age are listed in Table 1. There were
a greater number of women in the 50 years group but the
severity of disease as classified by GOLD stage was similar
to the total population. Approximately half of the patients
were in GOLD stage II. Conversely, despite the relatively
young age of this subpopulation, nearly 50% had severe or
very severe disease with an average FEV1 percent pre-
dicted that was comparable to that in the older age
groups. Approximately half of the 50 years cohort
continued to smoke, whereas there was a progressive
decrease in the percentage of continuing smokers with
age. Despite having similar objective indices of disease1 did not receive 
tiotropium
2987 assigned to tiotropium
2802 aged 
>50 years received 
tiotropium
184 aged ≤50 years 
received tiotropium
8020 patients a
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Figure 1 A CONSORT diagram descseverity, health-related quality of life was substantially
poorer in the patients under 50 years, as reflected in the
higher SGRQ score.
Use of concomitant medication in the younger age group
was high and similar to the total study population.
Approximately 50% of the younger patients were taking
inhaled corticosteroids and long acting beta agonists either
in a combination inhaler or as separate inhalers.
A total of 65 patients (38%) from the placebo group and
51 (28%) from the tiotropium group prematurely dis-
continued trial medication. More patients discontinued
from the placebo group compared to the tiotropium group
due to adverse events (21 vs. 13 patients) and because of
worsening COPD (11 vs. 4 patients).
Lung function outcome
The co-primary endpoints of rate of decline in pre and post-
bronchodilator FEV1 tended to be improved by tiotropium.
In the case of post-bronchodilator change in FEV1 this was
statistically significant at 58 ml/year vs. 38 ml/year;
p Z 0.01 (Table 2). This improvement in the rate of FEV1
decline appeared consistent across the treated population
and no association with possible confounding variables was
seen. The between group difference in the decline in pre-
bronchodilator FEV1 was 7 ml/year (p Z 0.34). The signif-
icant improvement in rate of decline in post-bronchodilator
FEV1 in patients 50 years is in contrast to the findings in
the total UPLIFT population. In the whole study population
annual decline in FEV1 was similar in both tiotropium and3006 assigned to placebo (control)
172 aged ≤50 years 
received placebo
2834 aged >50 years 
received placebo
ssessed 
lity
ndomised
2027 withdrew/did not 
meet entry criteria
107 completed the 
study
65 discontinued
21 had an adverse event
11 worsening COPD
42 administrative
3 protocol non-compliance
27 consent withdrawn
12 lost to follow up
2 other
ribing the flow of study patients.
Table 1 Baseline demographics of the tiotropium and control groups according to age.
50 years 50e60 years 60e70 years >70 years
Tiotropium
(n Z 184)
Control
(n Z 172)
Total
(n Z 356)
Total
(n Z 1563)
Total
(n Z 2511)
Total
(n Z 1562)
Male, % 61.4 58.1 59.8 70.0 75.8 80.9
Mean GOLD stage, %
II 50.5 47.7 49.2 46.4 45.0 45.3
III 37.0 35.5 36.2 41.5 44.9 46.7
IV 11.4 15.1 13.2 11.0 8.1 6.3
Smoking history, %
Ex-smoker 54.3 43.0 48.9 57.6 72.2 85.3
Current smoker 45.7 57.0 51.1 42.4 27.8 14.7
Mean COPD duration, yrs (SD) 7.1 (5.6) 7.8 (6.3) 7.4 (5.9) 8.8 (6.3) 10.1 (7.5) 10.8 (8.5)
Respiratory medication, %
LABA 55.4 59.3 57.3 58.5 60.5 61.8
ICS 56.0 60.5 58.1 60.3 61.9 63.8
Combination ICS þ LABA 45.1 47.7 46.3 48.2 48.7 50.1
Anticholinergic 39.1 35.5 37.4 42.9 46.0 48.6
Mean pre-bronchodilator (SD)
FEV1 (L) 1.28 (0.47) 1.20 (0.46) 1.24 (0.47) 1.18 (0.44) 1.09 (0.38) 0.99 (0.34)
FEV1 (% predicted) 39.6 (12.8) 38.5 (13.4) 39.1 (13.1) 39.1 (12.6) 39.4 (11.8) 39.8 (11.3)
FVC (L) 2.85 (0.84) 2.78 (0.92) 2.82 (0.87) 2.80 (0.85) 2.60 (0.80) 2.44 (0.75)
SVC (L) 2.99 (0.85) 2.93 (0.85) 2.96 (0.85) 2.95 (0.86) 2.79 (0.82) 2.62 (0.75)
Mean post-bronchodilator (SD)
FEV1 (L) 1.55 (0.52) 1.48 (0.53) 1.51 (0.52) 1.42 (0.48) 1.31 (0.42) 1.19 (0.37)
FEV1 (% predicted) 48.1 (13.9) 47.3 (15.0) 47.7 (14.4) 47.1 (13.3) 47.6 (12.4) 47.9 (12.0)
FVC (L) 3.32 (0.89) 3.27 (0.97) 3.30 (0.93) 3.28 (0.90) 3.09 (0.88) 2.86 (0.81)
SVC (L) 3.40 (0.89) 3.29 (0.93) 3.35 (0.91) 3.36 (0.92) 3.21 (0.89) 3.00 (0.81)
Mean SGRQ Total Score (SD) 48.2 (18.6) 48.2 (18.0) 48.2 (18.3) 48.0 (17.5) 44.9 (16.9) 44.8(16.6)
GOLD, Global Initiative for Chronic Obstructive Lung Disease; LABA, long-acting b-agonists; ICS, inhaled corticosteroids; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; SVC, slow vital capacity; SGRQ, St George’s Respiratory Questionnaire.
1662 A.H. Morice et al.placebo groups at 30 ml/year before bronchodilation and
40 ml/year (tiotropium) and 42 ml/year (control) after
bronchodilation. There was no significant difference in the
rate of decline of FVC or SVC in patients 50 years when
tiotropium was compared with controls.
There were sustained improvements in lung function
throughout the trial associated with tiotropium (Fig. 2a
and b). Both pre and post-bronchodilator FEV1 were
significantly greater in the tiotropium group than the
control group at all time points (p < 0.05). The differences
ranged from 82 to 148 ml and 58e172 ml, respectively.
Pre-bronchodilator FVC improvements in the tiotropium
group were significantly greater than the control at all
time points (p < 0.05) except for month 18. Post-bron-
chodilator FVC measurements were greater in theTable 2 Mean (SE) rate of decline (ml/yr) in pre-bronchodilato
patients 50 years old.
Tiotropium
Pre-bronchodilator FEV1 34 (5)
Post-bronchodilator FEV1 38 (5)
Pre-bronchodilator FVC 49 (11)
Post-bronchodilator FVC 52 (10)tiotropium group and this achieved statistical significance
for months 36 and 42.Health-related quality of life
Tiotropium was associated with improvements in the SGRQ
total score throughout the study period (Fig. 3) with this
improvement being statistically significant at half of the clinic
visits. The mean differences (tiotropium e control) were
3.3, 3.0 and 4.1 units at 1, 2 and 3 years in favour of
tiotropium. The mean difference was 3.9 at 42 months and
fell to þ0.9 units at 48 months. However at 48 months, SGRQ
total score datawere not available for 41.9% of patients in the
placebo group and 34.2% of patients in the tiotropium group.r and post-bronchodilator FEV1 in the tiotropium and control
Control Difference p-value
41 (5) 7 (7) 0.34
58 (6) 19 (8) 0.01
55 (11) 6 (5) 0.69
69 (11) 17 (15) 0.26
ab
Figure 2 Estimated mean pre and post-bronchodilator FEV1 (a) and FVC (b) throughout the UPLIFT trial in the tiotropium and
control groups in patients 50 years of age.
COPD in young patients 1663Exacerbations
The rate of exacerbations was significantly diminished by
treatment with tiotropium (Table 3) with a rate ratio of
0.73 (p Z 0.02). The hazard ratio (tiotropium/control) for
the first exacerbation was 0.87 (pZ 0.30). Hospitalisations
were infrequent in this population and there was no
significant difference between treatment arms.
Mortality
Mortality was relatively low in patients 50 years of age,
namely  7% for both treatment groups. Tiotropium was
associated with a lower mortality rate (Fig. 4) but this did
not reach statistical significance. For the protocol-defined
intention-to-treat period (including vital status informationuntil day 1440), the hazard ratio (95% CI) for tiotropium/
control was 0.77 (0.33, 1.79) and was based on 10 deaths in
the tiotropium group and 12 in the placebo group. The most
common cause of death was an exacerbation of COPD
(tiotropium 4, placebo 5). A specific cause of death could
not be determined in 4 cases (tiotropium 1, placebo 3). No
other events occurred in more than 2 patients in either
treatment group.
Interactions by age
Although tests for treatment interaction by age were con-
ducted, the interpretation is limited by either the sample
sizes within an age subgroup or the infrequency of an event
(i.e. fatal events). However, there was a significant inter-
action by age for pre-bronchodilator FEV1 (until month 36)
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Figure 3 Estimated mean St. George’s Respiratory Questionnaire total score throughout the UPLIFT trial in the tiotropium and
control groups in patients 50 years of age.
1664 A.H. Morice et al.and for pre-bronchodilator FVC (throughout the trial),
which could be suggestive of a difference in the magnitude
of treatment benefit across age groups.
Discussion
The UPLIFT trial was a 4-year randomized, double-blind
trial involving 5992 patients who received tiotropium
HandiHaler 18 mcg daily for up to 4 years. The size and the
duration of the trial along with the inclusion and exclusion
criteria resulted in a broad selection of patients, which is
conducive to examination of subgroups that might be of
particular medical and scientific interest. One such pop-
ulation comprises patients who would be considered as
being relatively young for the development of moderate to
very severe COPD. A total of 356 patients 50 years of age
were identified. Treatment with tiotropium resulted in
a significant slowing of the annualized rate of decline in
post-bronchodilator, but not pre-bronchodilator FEV1 along
with sustained improvements in lung function relative to
placebo throughout 4 years. As well, a reduced rate of
exacerbations and improvements in health-related quality
of life were observed, although not all exacerbation vari-
ables and SGRQ differences achieved nominal statistical
significance.Table 3 Exacerbation outcomes in the tiotropium and control
Tiotrop
(n Z 18
Number of exacerbations/patient year, mean (95% CI)a 0.59 (0.
Time to first exacerbation, median months (95% CI)b 16.4 (11
Number of hospitalizations for exacerbation/
patient year, mean (95% CI)a
0.13 (0.
CI, confidence interval; RR, rate ratio; HR, hazard ratio.
a Estimated using Poisson regression with Pearson over dispersion m
b Calculated using Cox regression.The major novel finding of this subgroup analysis is the
significant effect of tiotropium on one of the co-primary
endpoints, rate of decline in post-bronchodilator FEV1. The
magnitude of the reduction in the rate of decline of FEV1
over time with tiotropium appears larger for the post-
bronchodilator value compared to the pre-bronchodilator
value. It is possible that the post-bronchodilator FEV1 is
a more stable value in that essentially all influence of
bronchomotor tone has been removed (i.e. salbutamol 4
actuations þ ipratropium 4 actuations sequentially admin-
istered to achieve peak effects of both). The pre-bron-
chodilator value theoretically remains subject to circadian
variation and the potential external influences on smooth
muscle tone. The effects of this may be more prominent
over time given that the disease is progressive (i.e. a given
degree of smooth muscle tone on the radius will be
inversely proportional to the 4th power of the radius).
A similar outcome has recently been reported in the
UPLIFT subpopulation with GOLD stage II disease.10 Whilst
some of the patients reported in the latter subgroup anal-
ysis are also included in this current analysis, they repre-
sent only half of the population studied. That similar
findings have been revealed by two sub-analyses suggests
a potentially disease modifying effect of long-term tio-
tropium, and provides great impetus for the early detectionpatients 50 years old.
ium
4)
Control
(n Z 172)
Ratio
(tiotropium/control)
(95% CI)
p-value
49, 0.72) 0.81 (0.68, 0.97) RR 0.73 (0.56, 0.95) 0.02
.3, 20.1) 10.5 (6.9, 17.6) HR 0.87 (0.68, 1.13) 0.30
09, 0.19) 0.14 (0.09, 0.21) RR 0.93 (0.52, 1.67) 0.82
odel adjusting for time at risk.
0 5 10
On-treatment including
vital status (until Day
1470)
On-treatment including
vital status (until Day
1440)
On-treatment (until Day
1470)
Tiotropium
Control
H)%(etarytilatroM azard ratio (95% CI)
0 1 2
0.85 (0.37, 1.92); P=0.69
0.58 (0.24, 1.42); P=0.24
Favors 
tiotropium
Favors 
control
0.77 (0.33, 1.79); P=0.55
*Hazard ratio (control vs. tiotropium) and p-value were estimated using Cox regression with treatment, GOLD stage, and treatment by GOLD stage 
interaction as covariates. Observations were censored at 1470 days.
Figure 4 Mortality rates and hazard ratios (tiotropium/control) in patients 50 years of age.
COPD in young patients 1665and treatment of this condition. Several small scale surveys
looking at the rate of detection of COPD in primary care
settings worldwide demonstrate that many patients with
early stage disease remain undetected and under-
treated.12e14 If the object of treatment is purely symp-
tomatic relief then this may be considered acceptable.
However, if disease progression can be halted then
community surveillance in younger patients and those with
milder disease becomes imperative.
In both GOLD stage II and in patients 50 years of age in
UPLIFT, the post-bronchodilator decline in FEV1 was signifi-
cantly diminished by tiotropium therapy. In contrast whilst
the pre-bronchodilator FEV1 decline was numerically less in
the tiotropium than the placebo group this difference did not
achieve statistical significance. It is likely that there are
several disease processes at play in the pathology of COPD,
including mucus hypersecretion, parenchymal destruction
and an increase in cholinergic tone, chronic inflammation in
small airways with fibrotic thickening and the effect of
exacerbations.15e17 The differential expression of these
pathological processes may explain the different pheno-
types, such as emphysema and chronic bronchitis, seen
within COPD. It appears from the longitudinal spirometric
observations that tiotropiummay influenceCOPD inadisease
modifying fashion, aneffectwhich is revealedby the removal
of airways tone following bronchodilation. The administra-
tion of study drug, 80 mcg ipratropium and 400 mcg salbu-
tamol at appropriate timingswill induce full relaxation of the
airway minimising any tonic bronchospasm. Airflow limita-
tion will then reflect non-muscular airway collapse,
secondary to the loss of the parenchymal scaffold, mucus
plugging and airway wall thickening. The slower decline in
post-bronchodilator FEV1 with tiotropium may, because of
sustained bronchodilation and reduction in airway collapse,
lessen airway inflammation and consequently decrease lung
destruction. Pre-bronchodilator FEV1 changes may be
masked by the relative impact of, and the diurnal variability
in, the increased airway tone which characterises COPD.This subgroup analysis of patients 50 years or younger
from the UPLIFT trial dataset confirms that the previously
demonstrated benefits seen in the whole study population
also apply to younger patients. Treatment with tiotropium
is associated with a sustained bronchodilation with values
only returning to pre-study baseline towards the end of the
four year study period. The degree of bronchodilation seen
was similar to that observed in the whole UPLIFT population
when compared to placebo (increase in pre-bronchodilator
FEV1 ranged from 87 to 103 ml throughout the trial for the
entire population).
Tiotropium improved SGRQ and reduced exacerbations
during the UPLIFT study in patients 50 years of age. The
size of the effect for the SGRQ total score, however, was
at the borderline of the reported minimal clinically
importance difference of 4 units. The high baseline SGRQ
indicates that the quality of life of these younger patients
with COPD was significantly impacted by their disease. The
lack of difference between placebo and tiotropium treat-
ment seen at 48 months may reflect the considerably
fewer numbers of patients from whom data was obtained
at this time point for this particular assessment of SGRQ
and possible effects from preferential discontinuation of
more severely afflicted patients in the control group.
Regarding exacerbations, there was a lower rate in the
patients  50 years than in the whole UPLIFT population
(0.59 (tiotropium) vs. 0.81 (placebo) per patient year), but
the reduction associated with tiotropium therapy is
consistent with that seen in the whole study population.
The hazard ratio for time to first exacerbation indicated
a reduction in risk, although the confidence interval
included 1, which likely reflects the smaller sample size of
the subgroup (and corresponding loss of precision of the
estimate).
Evaluation of baseline characteristics revealed the
presence of significant COPD in younger patients. When
baseline spirometry is taken as percent predicted then
there is a remarkable similarity of the FEV1 in each decade
1666 A.H. Morice et al.in the UPLIFT population. Mean FEV1 varies between 38
and 40% of predicted. An obvious hypothesis to explain the
early onset of COPD in the younger patient is that they
have worse disease with an increased rate of deterioration
to severe airflow obstruction at an earlier age. The
observed rate of decline of pre-bronchodilator FEV1 in the
placebo treated group is 30 ml/year in the total UPLIFT
population compared to 41 ml/year in our younger pop-
ulation. The latter slope approximates to the rate of
decline needed to achieve the degree of baseline airflow
obstruction seen here, provided that the disease started
when the patient took up smoking. Older patients with
a slower rate of lung function decline may therefore have
a delay in the onset of moderate to severe airflow
obstruction; alternatively, their lung function may have
started to decline at an accelerated rate at an older age.
Younger patients had fewer pack years (mean 33 years)
compared to the 45 pack years of the older cohort, but
being chronologically younger they will have had greater
annual tobacco consumption. Another possible explanation
is a natural section of individuals with a slower rate of
decline based on the interaction of genetics and environ-
ment permitting prolonged survival with COPD.
As stated, these younger patients had a similar disease
profile in terms of FEV1 % predicted and GOLD staging
compared to the whole UPLIFT population. Despite this
similarity, patients reported at baseline a lower (i.e. worse)
health-related quality of life than older patients. It is
possible that this greater impairment is due to the greater
impact of the symptoms of COPD in a normally more active,
younger population. The population of younger patients in
the UPLIFT study, with early onset of disease and a rapid
lung function decline, might represent a unique phenotype
and possibly genotype.
Women comprised 40% of the patients50 years in UPLIFT.
This may represent an increase in the proportion of younger
women smoking in the general population and is reflected by
a worldwide increase in women with COPD, as well as hospi-
talisations and deaths due to COPD.18,19 Whether there are
important sexes related differences in the development or
progression of COPD or in response to treatment has been
much debated. The difference in the number of women in the
younger subgroup compared to that in the older age groups is
relatively small, however, and would not be expected to
influence the findings of this analysis.
In the entire UPLIFT population there is a progressive
decrease in the percentage of active smokers with
increasing age. Over half of the patients aged <50 reported
continued smoking compared with less than 15% of patients
aged over 70 years. There could be several explanations for
this observation. First, smoking cessation frequently
requires multiple attempts before successful quitting is
achieved.20 Older patients will therefore have a longer time
to undertake serial efforts. Continued smoking not only
increases the decline in lung function with COPD but also
puts the smoker at risk of many other smoking-related
disorders. It is possible that a high rate of attrition from
other smoking-related diseases is responsible for
a progressive loss of smokers from the age profile. It is
interesting to note that continued smoking appeared to
counterbalance the beneficial effect of tiotropium on
mortality seen in the whole UPLIFT population.21 Incontrast to the similar GOLD staging and lower quality of
life seen in the patients aged 50 years and younger, abso-
lute baseline spirometric values were higher than for the
rest of the study population. Thus, this population illus-
trates the marked age dependency of the metrics used in
our assessment of COPD. We also acknowledge that the
upper limit of FEV1 for inclusion was 70% predicted and
further data should be generated in younger patients with
milder disease.
As with any subgroup analysis, even if pre-specified,
there are a number of limitations inherent in this methol-
ogy. Since patients were recruited from pulmonary
specialty practices it is likely that the patient population
studied does not reflect that seen in primary care. The ten
year follow-up of the European Community Respiratory
Health Survey demonstrates that 6% of younger people have
spirometry values below that required to achieve GOLD
stage II COPD.2 Symptomatic patients had a greater rate of
decline in lung function than those who were asymptom-
atic.22 Similarly, the population reported here was required
to have physician diagnosed COPD and therefore likely
reflects symptomatic patients who sought medical atten-
tion rather than those with merely reduced spirometry
perhaps identified through screening.
This analysis of patients 50 years who took part in the
UPLIFT study has demonstrated improvements in lung
function, quality of life and exacerbation frequency with
tiotropium treatment, indicating the benefits of mainte-
nance pharmacotherapy in younger patients with COPD.
Furthermore, the reduction in the decline in post-bron-
chodilator FEV1 with tiotropium suggests that, in addition
to providing symptomatic benefits and reduced rate of
exacerbations, continued treatment may reduce disease
progression. The analysis presented provides a justification
and rationale for early diagnosis and treatment in young
patients with COPD.
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